Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 66Lymphoma 55Multiple Myeloma 54Breast Neoplasms 49Neoplasm Metastasis 48Prostatic Neoplasms 46Lung Neoplasms 46Leukemia, Myeloid, Acute 39Ovarian Neoplasms 37Carcinoma, Non-Small-Cell Lung 37Melanoma 36Hematologic Neoplasms 35Colorectal Neoplasms 33Glioma 28Pancreatic Neoplasms 27Lymphoma, Non-Hodgkin 27Sarcoma 25Urinary Bladder Neoplasms 24Carcinoma, Renal Cell 24Brain Neoplasms 24Myelodysplastic Syndromes 22Neuroblastoma 21Fallopian Tube Neoplasms 19Triple Negative Breast Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Stomach Neoplasms 17Small Cell Lung Carcinoma 17Burkitt Lymphoma 17Glioblastoma 16Ependymoma 16

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Processes × 90 days × Clear all
NCT05797246 2026-05-22

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡